Current concepts in neuro-oncology: The cell cycle-A review

Neurosurgery

Volumn 40, Issue 5, 1997, Pages 1000-1015

  Dirks, Peter B ^a,b   Rutka, James T ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Astrocytomas; Cell cycle; Cyclin dependent kinases; Cyclins; Cyrin dependent kinase inhibitors; Retinoblasoma protein

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; PROTEIN KINASE; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F;

ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CANCER CELL; CELL CYCLE; CELL PROLIFERATION; DELETION MUTANT; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE TRANSFER; MOLECULAR BIOLOGY; PHOSPHORYLATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE;

EID: 0030985964     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-199705000-00025     Document Type: Article

References (162)

1. Arap W, Nishikawa R, Furnari F, Cavenee WK, Huang HJ: Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res 55:1351-1355, 1995.
2. 1. Genes Dev 7:812-821, 1993.
3. Bartkova J, Lukas J, Strauss M, Bartek J: Cyclin D1 oncoprotein accumulates in malignancies of diverse histogenesis. Oncogene 10:775-778, 1995.
4. Beijersbergen RL, Bernards R: Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins. Biochim Biophys Acta 1287:103-120, 1996.
5. Bhatia K, Fan S, Spangler G, Weintraub M, O'Connor PM, Judde JG, Magrath I: A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma. Cancer Res 55:1431-1435, 1995.
6. Bohmer RM, Scharf E, Assoian RK: Cytoskeletal integrity is required throughout the mitogen stimulation phase of the cell cycle and mediates anchorage-dependent expression of cyclin A. Mol Biol Cell 7:101-111, 1996.
7. Buchovich K, Duffy LA, Harlow E: The retinoblastoma protein is phosphorylated during specific phases of cell cycle. Cell 58: 1097-1105, 1989.
8. Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CK, Musgrove EA, Sutherland RL: Expression and amplification of cyclin genes in human breast cancer. Oncogene 8:2127-2133, 1993.
9. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE: Frequent somatic mutations and homozygous deletions of the (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8:27-32, 1994.
10. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie B, Murphree AL, Strong LC, White RL: Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305:779-784, 1983.
11. Cobrink D, Lee MH, Hannon G, Mulligan G, Bronson RT, Dyson N, Harlow E, Beach D, Weinberg RA, Jacks T: Shared role of the pRb-related p130 and p107 proteins in limb development. Genes Dev 10:1633-1644, 1996.
12. Costello JF, Berger MS, Huang HJ, Cavenee WK: Silencing of p16/CDKN2 expression in human gliomas by methylation and chromosome condensation. Cancer Res 56:2405-2410, 1996.
13. DeCaprio JA, Ludlow JW, Lynch D, Furukawa Y, Griffin J, Pinwica-Worms H, Huang C, Livingston DM: The product of the retinoblastoma gene has properties of a cell cycle regulatory element. Cell 58:1085-1095, 1989.
14. 1 checkpoint control. Cell 62:675-684, 1996.
15. Dirks PB, Hubbard SL, Murakami M, Rutka JT: Cyclin and cyclin-dependent kinase expression in human astrocytoma cell lines. J Neuropath Exp Neurol 56:291-300, 1997.
16. Donehower LA, Harvey M, Slage BT, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356: 215-221, 1992.
17. Dreyling MH, Bohlander SK, Adeyanju MO, Olopade OI: Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization. Cancer Res 55:984-988, 1995.
18. 1 arrest. Cell 76:1013-1023, 1994.
19. Dutta A, Chandra R, Leiter LM, Lester S: Cyclins as markers of proliferation: Immunocytochemical studies in breast cancer. Proc Natl Acad Sci U SA 92:5386-5390, 1995.
20. 1 arrest and apoptosis. Cancer Res 54:1169-1174, 1994.
21. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer E, Kinzler KW, Vogelstein B: WAF 1: A potential mediator of p53 tumor suppression. Cell 75:817-825, 1993.
22. Elledge SJ, Harper JW: CDK inhibitors: On the threshold of checkpoints and development. Curr Opin Cell Biol 6:847-852, 1994.
23. Ewen ME: The cell cycle and the retinoblastoma protein family. Cancer Metastasis Rev 13:45-66, 1994.
24. Farnham PJ, Slansky JE, Kollmar R: The role of E2F in the mammalian cell cycle. Biochim Biophys Acta 1155:125-131, 1993.
25. kip1-deficient mice. Cell 85:733-744, 1996.
26. Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin WG, Livingston DM, Orkin SH, Greenberg ME: E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 85:549-561, 1996.
27. Fisher RP, Morgan DO: A novel cyclin associates with MO15/ CDK7 to form the CDK-activating kinase. Cell 78:713-724, 1994.
28. Fraser A, Evan G: A license to kill. Cell 85:781-784, 1996.
29. Gerdes J, Lemke H, Baish H, Wacker H-H, Schwab U, Stein H: Cell cycle analysis of a proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710-1715, 1984.
30. Gerdes J, Schwab U, Lemke H, Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31:13-20, 1983.
31. Giani C, Finocchiaro G: Mutation rate of CDKN2 gene in malignant glioma. Cancer Res 54:6338-6339, 1994.
32. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G: Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54:1812-1817, 1994.
33. Gong J, Ardelt B, Tragnos F, Darzynkiewicz Z: Unscheduled expression of cyclin B1 and cyclin E in several leukemic and solid tumor cell lines. Cancer Res 54:4285-4288, 1994.
34. Goodrich DW, Lee WH: Molecular characterization of the retinoblastoma susceptibility gene. Biochim Biophys Acta 1155:43-61, 1993.
35. 1/S control of anchorage-independent growth in the fibroblast cell cycle. J Cell Biol 115:1419-1425, 1991.
36. Guadagno TM, Ohtsubo M, Roberts JM, Assoian RK: A link between cyclin A expression and adhesion-dependent cell cycle progression. Science 262:1572-1575, 1993.
37. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371:257-261, 1994.
38. 1 cyclin-dependent kinases. Cell 75:805-816, 1993.
39. Hartwell LH, Kastan MB: Cell cycle control and cancer. Science 266:1821-1828, 1994.
40. Harvey M, Vogel H, Lee EY, Bradley A, Donehower LA: Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin. Cancer Res 55:1146-1151, 1995.
41. He J, Allen JR, Collins VP: CDK4 amplification is an alternative mechanism to p16 homozygous deletion in glioma cell lines. Cancer Res 54:5804-5807, 1994.
42. Hengst L, Dulic V, Slingerland J, Lees E, Reed SI: A cell cycle regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci U S A 91:5291-5295, 1994.
43. Heichman KA, Roberts JM: Rules to replicate by. Cell 79:557-562, 1994.
44. INK4B. Cancer Res 56:722-727, 1996.
45. Hinds PW, Dowdy SF, Eaton EN, Arnold A, Weinberg RA: Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci U S A 91:709-713, 1994.
46. Hoshino T, Wilson CB: Cell kinetic analyses of human malignant brain tumors (gliomas). Cancer 44:956-962, 1979.
47. Hoshino T, Knebel KD, Rosenblum ML, Dougherty DV, Wilson CB: Clonogenicity of multiple populations of human glioma cells in vitro sorted by DNA content. Cancer 50:997-1002, 1982.
48. Hoshino T, Nagashima T, Murovic JA, Wilson CB, Edwards MSG, Gutin PH, Davis RL, DeArmond SJ: In situ cell kinetics studies on human neuroectodermal tumors with bromodeoxyuridine labeling. J Neurosurg 64:453-459, 1986.
49. Hoshino T, Nomura K, Wilson CB, Knebel KD, Gray JW: The distribution of nuclear DNA from human brain tumor cells: Flow cytometric studies. J Neurosurg 49:13-21, 1978.
50. Hu N, Gutsmann A, Herbert DC, Bradley A, Lee WH, Lee EY: Heterozygous Rb-1Δ20/+ mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 9:1021-1027, 1994.
51. Hunter T, Pines J: Cyclins and cancer: II - Cyclin D and CDK inhibitors come of age. Cell 79:573-582, 1994.
52. Hussussian CJ, Struewing JP, Golstein AM, Higgins RA, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA, Dracopoli NC: Germline p16 mutations in familial melanoma. Nat Genet 8:15-21, 1994.
53. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA: Effects of an Rb mutation in the mouse. Nature 359:295-300, 1992.
54. Jares P, Fernandez PL, Campo E, Nadal A, Bosch F, Aiza G, Nayach I, Traserra J, Cardesa A: PRAD1/cyclin D1 gene amplification correlates with mRNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Res 54:4813-4817, 1994.
55. Jen JJ, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Wilson JK, Kinzler K, Vogelstein B: Deletion of p16 and p15 in brain tumors. Cancer Res 54:6353-6358, 1994.
56. Jiang W, Kahn SM, Tomita N, Zhang YJ, Lu SH, Weinstein IB: Amplification and expression of human cyclin D gene in esophageal cancer. Cancer Res 52:2980-2983, 1992.
57. Jiang W, Kahn SM, Zhou P, Zhang YJ, Cacace AM, Infante AS, Doi S, Santella RM, Weinstein IB: Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression, gene expression. Oncogene 8:3447-3457, 1993.
58. Jiang W, Zhang YJ, Kahn SM, Hollstein MC, Santella RM, Lu SH, Harris CC, Montesano R, Weinstein IB: Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci U S A 90:9026-9030, 1993.
59. Johnson DG, Schwarz JK, Cress WD, Nevins JR: Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 365:349-352, 1993.
60. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RD, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in the genesis of many tumor types. Science 264:436-440, 1994.
61. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8:22-26, 1994.
62. Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilczynski S, Lee YY, Bartam CR, Koeffler HP: Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 55:2266-2269, 1995.
63. Kerr JF, Winterford CM, Harmon BV: Apoptosis: Its significance in cancer and cancer therapy. Cancer 73:2013-2026, 1994.
64. Keyomarsi K, Pardee AB: Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci USA 90:1112-1116, 1993.
65. Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB: Cyclin E: A potential prognostic marker for breast cancer. Cancer Res 54:380-385, 1994.
66. Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ, Look AT: Coamplification of CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res 53:5535-5541, 1993.
67. King RW, Jackson PK, Kirschner MW: Mitosis in transition. Cell 79:563-571, 1994.
68. kip1. Cell 85:721-732, 1996.
69. Knosp E, Kitz K, Perneczky A: Proliferation activity in pituitary adenomas: Measurement by monoclonal antibody Ki-67. Neurosurgery 25:927-930, 1989.
70. Knudson AG: Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68:820-823, 1971.
71. Ko LJ, Prives C: p53: Puzzle and paradigm. Genes Dev 10:1054-1072, 1996.
72. Koshland D: Mitosis: Back to basics. Cell 77:951-954, 1994.
73. Kyritsis AP, Zhang B, Zhang W, Xiao M, Takeshima H, Bondy ML, Cunningham JE, Levin VA, Bruner J: Mutations in the p16 gene in gliomas. Oncogene 12:63-67, 1996.
74. Laskey RA, Fairman MP, Blow JJ: S phase of the cell cycle. Science 246:609-614, 1989.
75. Leach FS, Elledge SJ, Sherr CJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B: Amplification of cyclin genes in colorectal carcinoma. Cancer Res 53:1986-1989, 1993.
76. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EY: Human retinoblastoma susceptibility gene: Cloning, identification, and sequence. Science 235:1394-1399, 1987.
77. Lee MH, Williams BO, Mulligan G, Mukai S, Bronson RT, Dyson N, Harlow E, Jacks T: Targeted disruption of p107: Functional overlap between p107 and pRb. Genes Dev 10:1621-1632, 1996.
78. Li Y, Nichols MA, Shay JW, Xiong Y: Transcriptioital repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product. Cancer Res 54:6078-6082, 1994.
79. Li R, Waga S, Hannon GJ, Beach D, Stillman B: Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371:534-537, 1994.
80. Lovec H, Grzeschiczek A, Kowalski MB, Moreoy T: Cyclin D1/ bcl-1 cooperates with myc genes in the generation of B-cell lymphomas in transgenic mice. EMBO J 13:3487-3495, 1994.
81. 1. J Cell Biol 125: 625-638, 1994.
82. Lukas J, Pagano M, Statkova Z, Draetta G, Bartek J: Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumor cell lines. Oncogene 9:707-718, 1994.
83. Marshall CJ: Tumor suppressor genes. Cell 64:313-326, 1991.
84. Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sheer CJ, Kato JY: D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol 14:2066-2076, 1994.
85. McIntosh JR, Koonce MP: Mitosis. Science 246:622-628, 1989.
86. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/ CDKN2/MTS1 in human cancers. Nat Med 1:686-692, 1995.
87. 1 kinase activity for CDK6, a novel cyclin D partner. Mol Cell Biol 14:2077-2086, 1994.
88. Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E, Balm A: Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 55:975-978, 1995.
89. Moran E: DNA tumor virus transforming proteins and the cell cycle. Curr Opin Genet Dev 3:63-70, 1993.
90. Morgan DO: Principles of CDK regulation. Nature 374:131-134, 1995.
91. Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM, Arnold A: A novel cyclin encoded by a bcl-1 linked-candidate oncogene. Nature 350:512-515, 1991.
92. Moulton T, Samara G, Chung WY, Yuan L, Desai R, Sisti M, Bruce J, Tycko B: MTS1/p16/CDKN2 lesions in primary glioblastomas multiforme. Am J Pathol 146:613-619, 1995.
93. Murray A: Creative blocks: Cell-cycle checkpoints and feedback controls. Nature 359:599-604, 1992.
94. Murray A, Hunt A: The Cell Cycle. New York, W.H. Freeman and Company, 1993.
95. kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85:707-720, 1996.
96. Nevins JR: E2F: A link between the Rb tumor suppressor protein and viral oncoproteins. Science 258:424-429, 1992.
97. Nigg EA: Targets of cyclin-dependent kinases. Curr Opin Cell Biol 5:187-193, 1993.
98. Nigg EA: Cyclin-dependent protein kinases: Key regulators of the cell cycle. Bioessays 17:471-480, 1995.
99. Nishida N, Fukuda Y, Komeda T, Kita R, Sando T, Furukawa M, Amenomori M, Shibagaki I, Nakao K, Ikenaga M, Ishizaki K: Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res 54:1941-1945, 1994.
100. Nishikawa R, Furnari FB, Lin H, Arap W, Berger MS, Cavenee WK, Huang HJ: Loss of p16 expression is frequent in high grade glioma. Cancer Res 55:1941-1945, 1995.
101. Nishizaki T, Orita T, Furutani Y, Ikeyama Y, Aoki H, Sasaki K: Flow-cytometric DNA analysis and immunohistochemical measurement of Ki-67 and BUdR labeling indices in human brain tumors. J Neurosurg 70:379-384, 1989.
102. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR: Cloning of senescent-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211:90-98, 1994.
103. Nurse P: Ordering S phase and M phase in the cell cycle. Cell 79:547-550, 1994.
104. 1 in mammalian fibroblasts. Science 259:1908-1912, 1993.
105. 1-S phase transition. Mol Cell Biol 15:2612-2624, 1995.
106. INK4 in human cancer. Proc Natl Acad Sci U S A 91:11045-11049, 1994.
107. kip2 in soft tissue sarcomas and Wilms' tumors. Cancer Res 56:1219-1221, 1996.
108. Otterson GA, Kratzke RA, Coxon A, Kim YW, Kaye FJ: Absence of p16 protein is restricted to the subset of lung cancer lines that retains wild-type Rb. Oncogene 9:3375-3378, 1994.
109. 1 events and regulation of cell proliferation. Science 246:603-608, 1989.
110. INK4A tumor suppressor gene product. EMBO J 14:503-511, 1995.
111. INK4 homozygous deletions and CDK4 gene amplifications. J Neurosurg 84:1020-1023, 1996.
112. kip1 gene to 12p13 and its analysis in leukemias. Cancer Res 55:1206-1210, 1995.
113. Pines J: Cyclins and cyclin-dependent kinases: A biochemical view. Biochem J 308:697-711, 1995.
114. kip1, a cyclin-CDK inhibitor, links transforming growth factor β and contact inhibition to cell cycle arrest. Genes Dev 8:9-22, 1994.
115. kip1, a cyclin-dependent kinase inhibitor and potential mediator of extracellular antimitogenic signals. Cell 78:59-66, 1994.
116. kip1: Chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 55:1211-1214, 1995.
117. Quastler H, Sherman FG: Cell population kinetics in the intestinal epithelium of the mouse. Exp Cell Res 17:420-438, 1959.
118. 1 phase in rodent fibroblasts. Genes Dev 7:1559-1571, 1993.
119. Raffel C, Ueki K, Harsh GR IV, Louis DN: The multiple tumor suppressor 1/cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive neuroectodermal tumor. Neurosurgery 36:971-975, 1995.
120. Reifenberger G, Reifenberger J, Ichimura K, Meltzer PS, Collins VP: Amplification of multiple genes from chromosomal region 12q13 in human malignant gliomas: Preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, MDM2. Cancer Res 54:4299-4303, 1994.
121. 1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 14:1669-1679, 1994.
122. Schabel FM: The use of tumor growth kinetics in planning "curative" chemotherapy of advanced solid tumors. Cancer Res 29:2384-2389, 1969.
123. Schmidt EE, Ichimura K, Reifenberger G, Collins VP: CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54:6321-6324, 1994.
124. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707, 1994.
125. Serrano M, Lee HW, Chin L, Cordon-Cardo C, Beach D, DePinho RA: Role of the INK4 locus in tumor suppression and cell mortality. Cell 85:27-37, 1996.
126. Shan B, Lee WH: Deregulated expression of E2F-1 induces S phase entry and leads to apoptosis. Mol Cell Biol 14:8166-8173, 1994.
127. 1 cyclins. Cell 73:1059-1065, 1993.
128. 1 phase progression: Cycling on cue. Cell 79:551-555, 1994.
129. 1 cyclin-dependent kinases. Genes Dev 9:1149-1163, 1995.
130. Shibata T, Burger PC: The use of the monoclonal antibody Ki-67 in determination of the growth fraction in pediatric brain tumors. Childs Nerv Syst 2:364-367, 1987.
131. Shiohara M, El-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yag R, Chen DL, Vogelstein B, Koeffler HP: Absence of WAF1 mutations in a variety of human malignancies. Blood 84:3781-3784, 1994.
132. Sidle A, Palaty C, Dirks P, Wiggan O, Kiess M, Gill RM, Wong AK, Hamel P: Activity of the retinoblastoma family proteins, pRb, p107, and p130, during cellular proliferation and differentiation. Crit Rev Biochem Mol Biol 31:237-271, 1996.
133. Siegers HP, Zuber P, Hamou M-F, Van Melle GD, de Tribolet N: The implications of the heterogeneous distribution of Ki-67 labelled cells in meningiomas. Br J Neurosurg 3:101-108, 1989.
134. Singh P, Wong SH, Hong W: Overexpression of E2F1 in rat embryo fibroblasts leads to neoplastic transformation. EMBO J 13:3329-3338, 1994.
135. Solomon MJ: Activation of the various cyclin/CDC2 protein kinases. Curr Opin Cell Biol 5:180-186, 1993.
136. Sonoda Y, Yoshimoto T, Sekiya T: Homozygous deletion of the MTS1l/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma. Oncogene 11:2145-2149, 1995.
137. kip1 mutation found in breast cancer. Cancer Res 56:2400-2404, 1996.
138. INK4 gene in human glioma cells. Oncogene 12:2029-2034, 1996.
139. Steller H: Mechanisms and genes of cellular suicide. Science 267:1445-1449, 1995.
140. Su TT, Follette PJ, O'Farrell PH: Qualifying for the license to replicate. Cell 81:825-828, 1995.
141. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 267:1456-1462, 1995.
142. Toyoshima H, Hunter T: p27, a novel inhibitor of cyclin-CDK protein kinase activity, is related to p21. Cell 78:68-74, 1994.
143. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN: CDKN2/p16 or Rb alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56:150-153, 1996.
144. Walker DG, Duan W, Popovic EA, Kaye AH, Tomlinson FH, Lavin M: Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas. Cancer Res 55:20-23, 1995.
145. Wang TC, Cardiff RD, Zuckerberg L, Lees E, Arnold A, Schmidt EV: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369:669-671, 1994.
146. Weinberg RA: Tumor suppressor genes. Science 254:1138-1146, 1991.
147. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81:323-330, 1995.
148. Weinberg RA: E2F and cell proliferation: A world turned upside down. Cell 85:457-459, 1996.
149. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T: Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet 7:480-484, 1994.
150. Withers DA, Harvey RC, Faust JB, Melnyk O, Carey K, Meeker TC: Characterization of a candidate bd-1 gene. Mol Cell Biol 11:4846-4853, 1991.
151. INK4A gene product in human pituitary tumors. Cancer Res 56:2493-2496, 1996.
152. Wuarin J, Nurse P: Regulating S phase: CDKs, licensing and proteolysis. Cell 85:785-787, 1996.
153. Xiong Y, Connolly T, Futcher B, Beach D: Human D-type cyclin. Cell 65:691-699, 1991.
154. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704, 1993.
155. Xiong X, Zhang H, Beach D: D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71:505-514, 1992.
156. Xiong Y, Zhang H, Beach D: Subunit arrangement of cyclin-dependent kinases is associated with cellular transformation. Genes Dev 7:1572-1583, 1993.
157. Xu G, Livingston DM, Krek W: Multiple members of the E2F transcription family are the products of oncogenes. Proc Natl Acad Sci U S A 92:1357-1361, 1995.
158. Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson NJ: Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 85:537-548, 1996.
159. Zariwala M, Liu E, Xiong Y: Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15 and p18 in tumor-derived cell lines and primary tumors. Oncogene 12:451-455, 1996.
160. Zhang H, Hannon GJ, Beach D: p21 containing cyclin kinases exist in both active and inactive states. Genes Dev 8:1750-1758, 1994.
161. Cip1-related domain to bind to cyclin/CDK2 and regulate interactions with E2F. Genes Dev 9:1740-1752, 1995.
162. Zuber P, Hamou M-F, de Tribolet N: Identification of proliferating cells in human gliomas using the monoclonal antibody Ki-67. Neurosurgery 22:364-368, 1988.